These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 28585707)

  • 41. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
    Ryan C; Kirby B; Collins P; Rogers S
    Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brodalumab for the treatment of psoriasis.
    Galluzzo M; D'adamio S; Bianchi L; Talamonti M
    Expert Rev Clin Immunol; 2016 Dec; 12(12):1255-1271. PubMed ID: 27718760
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
    Viswanathan HN; Mutebi A; Milmont CE; Gordon K; Wilson H; Zhang H; Klekotka PA; Revicki DA; Augustin M; Kricorian G; Nirula A; Strober B
    Value Health; 2017 Sep; 20(8):1174-1179. PubMed ID: 28964451
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recapture Rate of Brodalumab in Patients With a Lapse in Treatment.
    Lebwohl M; Cather J; Armstrong A; Van Voorhees A; Jacobson A
    J Drugs Dermatol; 2020 Apr; 19(4):384-387. PubMed ID: 32272515
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain.
    Galan-Gutierrez M; Font-Ugalde P; Padilla L; Hernandez-Montoya C; Godoy D; Armario-Hita JC; Ruiz-Villaverde R
    Int J Dermatol; 2023 May; 62(5):700-706. PubMed ID: 36495585
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
    Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N
    J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Brodalumab versus ustekinumab in psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
    [No Abstract]   [Full Text] [Related]  

  • 49. Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: A Narrative Review.
    Cannizzaro MV; Coscarella G; Chiricozzi A
    Dermatol Pract Concept; 2023 Jul; 13(3):. PubMed ID: 37557129
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.
    Lebwohl MG; Papp KA; Marangell LB; Koo J; Blauvelt A; Gooderham M; Wu JJ; Rastogi S; Harris S; Pillai R; Israel RJ
    J Am Acad Dermatol; 2018 Jan; 78(1):81-89.e5. PubMed ID: 28985956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial.
    Yao DN; Lu CJ; Wen ZH; Yan YH; Xuan ML; Li XY; Li G; He ZH; Xie XL; Deng JW; Guo XF; Ou AH
    Trials; 2016 Mar; 17(1):140. PubMed ID: 26983642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
    Kamili QU; Miner A; Hapa A; Menter A
    J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
    Puig L; Roé E; García-Navarro X; Corella F; Alomar A
    Clin Exp Dermatol; 2009 Jun; 34(4):469-75. PubMed ID: 19077105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.
    Ho VC; Griffiths CE; Albrecht G; Vanaclocha F; León-Dorantes G; Atakan N; Reitamo S; Ohannesson A; Mørk NJ; Clarke P; Pfister P; Paul C
    Br J Dermatol; 1999 Aug; 141(2):283-91. PubMed ID: 10468801
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies.
    Endres CJ; Salinger DH; Köck K; Gastonguay MR; Martin DA; Klekotka P; Nirula A; Gibbs MA
    J Clin Pharmacol; 2014 Nov; 54(11):1230-8. PubMed ID: 24846347
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.
    Wozel G; Vitéz L; Meurer M
    Acta Dermatovenerol Alp Pannonica Adriat; 2008 Sep; 17(3):133-6. PubMed ID: 18853077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapid and Sustained Improvement in a Patient With Plaque Psoriasis Switched to Brodalumab After Failing Treatment Clearance on Six Other Biologic Therapies.
    Haycraft K; Cooke L
    J Drugs Dermatol; 2020 Jan; 19(1):86-88. PubMed ID: 32023014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.